CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1109-1120

  Meng, Fanbin ^a   Li, Wan ^a   Li, Changling ^b   Gao, Zhigang ^a   Guo, Kejian ^a   Song, Shaowei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

CCL18; Epithelial mesenchymal transition; Invasion; Migration; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CCL18 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR 30; HERMES ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 8; PITPNM3 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; BETA CHEMOKINE; CCL18 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; U937 CELL LINE; CELL MOTION; GENETICS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; U937 CELLS;

EID: 84921926131     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2794     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Moore MJ: The treatment of advanced pancreatic cancer: current evidence and future challenges. Ann Oncol 19 (Suppl 7): vii304-vii308, 2008.
3. Stathis A and Moore MJ: Advanced pancreatic carcinoma: current reatment and future challenges. Nat Rev Clin Oncol 7: 163-172, 2010.
4. Hamada S, Masamune A and Shimosegawa T: Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 4: 331, 2013.
5. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR and Yang SM: Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012: 948098, 2012.
6. Chen J, Yao Y, Gong C, et al: CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19: 541-555, 2011.
7. Mantovani A: The chemokine system: redundancy for robust outputs. Immunol Today 20: 254-257, 1999.
8. Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127, 2000.
9. Sallusto F and Mackay CR: Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol 16: 724-731, 2004.
10. Bromley SK, Mempel TR and Luster AD: Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9: 970-980, 2008.
11. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP and Belperio JA: Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42: 768-778, 2006.
12. Ijichi H, Chytil A, Gorska AE, et al: Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121: 4106-4117, 2011.
13. Schraufstatter I, Takamori H, Sikora L, Sriramarao P and DiScipio RG: Eosinophils and monocytes produce pulmonary and activation-regulated chemokine, which activates cultured monocytes/macrophages. Am J Physiol Lung Cell Mol Physiol 286: L494-L501, 2004.
14. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, Julkunen I, Forster R, Burgstahler R, Lipp M and Lanzavecchia A: Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29: 1617-1625, 1999.
15. Pivarcsi A, Gombert M, Dieu-Nosjean MC, et al: CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cellderived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol 173: 5810-5817, 2004.
16. Schutyser E, Richmond A and Van Damme J: Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78: 14-26, 2005.
17. Schraufstatter IU, Zhao M, Khaldoyanidi SK and Discipio RG: The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology 135: 287-298, 2012.
18. Zhang B, Yin C, Li H, et al: Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3 β /Snail signalling pathway. Eur J Cancer 49: 3900-3913, 2013.
19. Li D, Duell EJ, Yu K, et al: Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 33: 1384-1390, 2012.
20. Sobin LH, Gospodarowicz MK and Wittekind CH (eds): International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell, Oxford, 2009.
21. Ni XG, Bai XF, Mao YL, et al: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31: 164-169, 2005.
22. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, Kurimoto K and Ohashi Y: Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 9: 735-740, 1994.
23. Harris P and Ralph P: Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 37: 407-422, 1985.
24. Daigneault M, Preston JA, Marriott HM, Whyte MK and Dockrell DH: The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocytederived macrophages. PLoS One 5: e8668, 2010.
25. Catusse J, Wollner S, Leick M, Schröttner P, Schraufstätter I and Burger M: Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol 225: 792-800, 2010.
26. Zissel Gl, Höhne K, Kilic A, Maier C, Goldmann T, Prasse A, Ploenes T, Trepel M, Eibel H and Müller-Quernheim J: Identification of the CCL18 receptor - effects of CCL18 on human lung fibroblasts in pulmonary fibrosis are mediated via CCR6. Pneumologie 66: P3-012, 2012.
27. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005.
28. Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I, Cañamero M, Rodriguez-Justo M, Serrano M and Barbacid M: Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19: 728-739, 2011.
29. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
30. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
31. Darash-Yahana M, Gillespie JW, Hewitt SM, et al : The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4: e6695, 2009.
32. Schutyser E, Struyf S, Proost P, et al : Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-24593, 2002.
33. Ploenes T, Scholtes B, Krohn A, Burger M, Passlick B, Müller-Quernheim J and Zissel G: CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential. PLoS One 8: e53068, 2013.
34. Günther C, Zimmermann N, Berndt N, Grosser M, Stein A, Koch A and Meurer M: Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 179: 1434-1442, 2011.
35. Plönes T, Krohn A, Burger M, Veelken H, Passlick B, Müller-Quernheim J and Zissel G: Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. PLoS One 7: e41746, 2012.
36. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ and Goodison S: CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 7: e37797, 2012.
37. Leung SY, Yuen ST, Chu KM, Mathy JA, Li R, Chan AS, Law S, Wong J, Chen X and So S: Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology 127: 457-469, 2004.
38. Fanelli MF, Chinen LT, Begnami MD, Costa WL Jr, Fregnami JH, Soares FA and Montagnini AL: The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology 61: 153-161, 2012.
39. Hao M, Zheng J, Hou K, Wang J, Chen X, Lu X, Bo J, Xu C, Shen K and Wang J: Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 84: 204-214, 2012.
40. Bertran E, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM, Vinyals A, Fabra A and Fabregat I: Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 21: 1595-606, 2009.